JP2008056680A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008056680A5 JP2008056680A5 JP2007239523A JP2007239523A JP2008056680A5 JP 2008056680 A5 JP2008056680 A5 JP 2008056680A5 JP 2007239523 A JP2007239523 A JP 2007239523A JP 2007239523 A JP2007239523 A JP 2007239523A JP 2008056680 A5 JP2008056680 A5 JP 2008056680A5
- Authority
- JP
- Japan
- Prior art keywords
- asthma
- bronchitis
- group
- bronchiectasis
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000006673 asthma Diseases 0.000 claims 19
- 206010006451 bronchitis Diseases 0.000 claims 15
- 201000009267 bronchiectasis Diseases 0.000 claims 9
- 239000005557 antagonist Substances 0.000 claims 5
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 239000003112 inhibitor Substances 0.000 claims 5
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 125000001475 halogen functional group Chemical group 0.000 claims 4
- 239000003199 leukotriene receptor blocking agent Substances 0.000 claims 4
- 206010014561 Emphysema Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 230000002757 inflammatory effect Effects 0.000 claims 3
- 201000010659 intrinsic asthma Diseases 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 208000023504 respiratory system disease Diseases 0.000 claims 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 229940122086 Adenosine A2a receptor agonist Drugs 0.000 claims 2
- 208000000884 Airway Obstruction Diseases 0.000 claims 2
- 102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 claims 2
- 108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 claims 2
- 206010006458 Bronchitis chronic Diseases 0.000 claims 2
- 229940122694 Muscarinic M3 receptor antagonist Drugs 0.000 claims 2
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 2
- 102000000551 Syk Kinase Human genes 0.000 claims 2
- 108010016672 Syk Kinase Proteins 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 239000002465 adenosine A2a receptor agonist Substances 0.000 claims 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 208000007451 chronic bronchitis Diseases 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 230000010250 cytokine signaling pathway Effects 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 208000024711 extrinsic asthma Diseases 0.000 claims 2
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 230000002458 infectious effect Effects 0.000 claims 2
- 239000003681 muscarinic M3 receptor antagonist Substances 0.000 claims 2
- 230000000414 obstructive effect Effects 0.000 claims 2
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 claims 2
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 claims 2
- 230000008506 pathogenesis Effects 0.000 claims 2
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims 2
- 229940044551 receptor antagonist Drugs 0.000 claims 2
- 239000002464 receptor antagonist Substances 0.000 claims 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims 2
- 102000004023 5-Lipoxygenase-Activating Proteins Human genes 0.000 claims 1
- 108090000411 5-Lipoxygenase-Activating Proteins Proteins 0.000 claims 1
- 206010003557 Asthma exercise induced Diseases 0.000 claims 1
- 206010003645 Atopy Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 206010006448 Bronchiolitis Diseases 0.000 claims 1
- 206010006482 Bronchospasm Diseases 0.000 claims 1
- 229940124638 COX inhibitor Drugs 0.000 claims 1
- 206010011416 Croup infectious Diseases 0.000 claims 1
- 101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 claims 1
- 101100135868 Dictyostelium discoideum pde3 gene Proteins 0.000 claims 1
- 102000015554 Dopamine receptor Human genes 0.000 claims 1
- 108050004812 Dopamine receptor Proteins 0.000 claims 1
- 208000000059 Dyspnea Diseases 0.000 claims 1
- 206010013975 Dyspnoeas Diseases 0.000 claims 1
- 229940122858 Elastase inhibitor Drugs 0.000 claims 1
- 208000004657 Exercise-Induced Asthma Diseases 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 229940122236 Histamine receptor antagonist Drugs 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 239000003458 I kappa b kinase inhibitor Substances 0.000 claims 1
- 208000016300 Idiopathic chronic eosinophilic pneumonia Diseases 0.000 claims 1
- 108010008212 Integrin alpha4beta1 Proteins 0.000 claims 1
- 102000005741 Metalloproteases Human genes 0.000 claims 1
- 108010006035 Metalloproteases Proteins 0.000 claims 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 229940123263 Phosphodiesterase 3 inhibitor Drugs 0.000 claims 1
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 claims 1
- 101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 claims 1
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 claims 1
- 108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 claims 1
- 208000010362 Protozoan Infections Diseases 0.000 claims 1
- 239000000150 Sympathomimetic Substances 0.000 claims 1
- 102000003141 Tachykinin Human genes 0.000 claims 1
- 206010054094 Tumour necrosis Diseases 0.000 claims 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 206010069351 acute lung injury Diseases 0.000 claims 1
- 239000000533 adrenergic alpha-1 receptor agonist Substances 0.000 claims 1
- 239000000384 adrenergic alpha-2 receptor agonist Substances 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 239000013566 allergen Substances 0.000 claims 1
- 201000009961 allergic asthma Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000000954 anitussive effect Effects 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 239000003434 antitussive agent Substances 0.000 claims 1
- 229940124584 antitussives Drugs 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 230000007885 bronchoconstriction Effects 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 239000000812 cholinergic antagonist Substances 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 201000009323 chronic eosinophilic pneumonia Diseases 0.000 claims 1
- 229940111134 coxibs Drugs 0.000 claims 1
- 229960000265 cromoglicic acid Drugs 0.000 claims 1
- 201000010549 croup Diseases 0.000 claims 1
- 239000003260 cyclooxygenase 1 inhibitor Substances 0.000 claims 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims 1
- 239000000850 decongestant Substances 0.000 claims 1
- 229940124581 decongestants Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003602 elastase inhibitor Substances 0.000 claims 1
- 230000007613 environmental effect Effects 0.000 claims 1
- 230000005713 exacerbation Effects 0.000 claims 1
- 208000024695 exercise-induced bronchoconstriction Diseases 0.000 claims 1
- 239000003172 expectorant agent Substances 0.000 claims 1
- 230000002538 fungal effect Effects 0.000 claims 1
- 239000003395 histamine H3 receptor antagonist Substances 0.000 claims 1
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 230000001861 immunosuppressant effect Effects 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims 1
- 230000002427 irreversible effect Effects 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 238000002483 medication Methods 0.000 claims 1
- 230000000510 mucolytic effect Effects 0.000 claims 1
- 229940066491 mucolytics Drugs 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 208000007892 occupational asthma Diseases 0.000 claims 1
- 244000052769 pathogen Species 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 230000001991 pathophysiological effect Effects 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 claims 1
- 239000002570 phosphodiesterase III inhibitor Substances 0.000 claims 1
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 229940127230 sympathomimetic drug Drugs 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 108060008037 tachykinin Proteins 0.000 claims 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 claims 1
- 229960000278 theophylline Drugs 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 229960005356 urokinase Drugs 0.000 claims 1
- 239000005526 vasoconstrictor agent Substances 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 0 *c1c(CC(C2)N(*)N)c2c(*)c(*)c1* Chemical compound *c1c(CC(C2)N(*)N)c2c(*)c(*)c1* 0.000 description 1
- LWMPFIOTEAXAGV-UHFFFAOYSA-N NN1CCCCC1 Chemical compound NN1CCCCC1 LWMPFIOTEAXAGV-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04290767 | 2004-03-23 | ||
| EP04290767.5 | 2004-03-23 | ||
| GB0425054A GB0425054D0 (en) | 2004-03-23 | 2004-11-12 | Formamide derivatives for the treatment of diseases |
| GB0425054.4 | 2004-11-12 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007504493A Division JP4033892B2 (ja) | 2004-03-23 | 2005-03-10 | アドレナリン受容体として有用なホルムアミド誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008056680A JP2008056680A (ja) | 2008-03-13 |
| JP2008056680A5 true JP2008056680A5 (enExample) | 2008-04-24 |
| JP4819770B2 JP4819770B2 (ja) | 2011-11-24 |
Family
ID=35432183
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007504493A Expired - Fee Related JP4033892B2 (ja) | 2004-03-23 | 2005-03-10 | アドレナリン受容体として有用なホルムアミド誘導体 |
| JP2007239523A Expired - Fee Related JP4819770B2 (ja) | 2004-03-23 | 2007-09-14 | アドレナリン受容体として有用なホルムアミド誘導体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007504493A Expired - Fee Related JP4033892B2 (ja) | 2004-03-23 | 2005-03-10 | アドレナリン受容体として有用なホルムアミド誘導体 |
Country Status (30)
| Country | Link |
|---|---|
| JP (2) | JP4033892B2 (enExample) |
| KR (1) | KR100806478B1 (enExample) |
| AR (1) | AR050236A1 (enExample) |
| AT (1) | ATE469121T1 (enExample) |
| CA (1) | CA2560547C (enExample) |
| CY (1) | CY1112549T1 (enExample) |
| DE (1) | DE602005021472D1 (enExample) |
| DK (1) | DK1730103T3 (enExample) |
| DO (1) | DOP2005000045A (enExample) |
| EA (1) | EA010133B1 (enExample) |
| ES (1) | ES2343808T3 (enExample) |
| GB (1) | GB0425054D0 (enExample) |
| GE (1) | GEP20084455B (enExample) |
| HN (1) | HN2005000118A (enExample) |
| HR (1) | HRP20100402T1 (enExample) |
| IL (1) | IL178102A (enExample) |
| IS (1) | IS8552A (enExample) |
| MA (1) | MA28480B1 (enExample) |
| MX (1) | MXPA06011019A (enExample) |
| MY (1) | MY144103A (enExample) |
| NL (1) | NL1028597C2 (enExample) |
| NO (1) | NO20064806L (enExample) |
| NZ (1) | NZ549839A (enExample) |
| PE (1) | PE20060264A1 (enExample) |
| PT (1) | PT1730103E (enExample) |
| RS (1) | RS51438B (enExample) |
| SI (1) | SI1730103T1 (enExample) |
| SV (1) | SV2005002056A (enExample) |
| TW (1) | TWI335312B (enExample) |
| UY (1) | UY28819A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8481569B2 (en) | 2008-04-23 | 2013-07-09 | Takeda Pharmaceutical Company Limited | Iminopyridine derivatives and use thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2005492A6 (es) * | 1987-12-23 | 1989-03-01 | Lasa Lab | Procedimiento de obtencion de n-(2-hidroxi-5-(1-hidroxi-2((2- (4-metoxifenil)-1metiletil)amino)etil)fenil)foramida (i). |
| CH686869A5 (de) * | 1991-04-05 | 1996-07-31 | Sepracor Inc | Beta (2) -bronchienerweiternde Arzneistoffe in Form ihrer Bronchienerweiternden Enantiomeren zur Verwendung fuer die Herstellung eines Mittels zur verbesserten Therapie. |
| OA11558A (en) * | 1999-12-08 | 2004-06-03 | Advanced Medicine Inc | Beta 2-adrenergic receptor agonists. |
| UA73965C2 (en) * | 1999-12-08 | 2005-10-17 | Theravance Inc | b2 ADRENERGIC RECEPTOR ANTAGONISTS |
| TWI249515B (en) * | 2001-11-13 | 2006-02-21 | Theravance Inc | Aryl aniline beta2 adrenergic receptor agonists |
| US6653323B2 (en) * | 2001-11-13 | 2003-11-25 | Theravance, Inc. | Aryl aniline β2 adrenergic receptor agonists |
| AU2003239880A1 (en) * | 2002-05-28 | 2003-12-12 | Theravance, Inc. | ALKOXY ARYL Beta2 ADRENERGIC RECEPTOR AGONISTS |
| US7317102B2 (en) * | 2003-04-01 | 2008-01-08 | Theravance, Inc. | Diarylmethyl and related compounds |
| US7268147B2 (en) * | 2003-05-15 | 2007-09-11 | Pfizer Inc | Compounds useful for the treatment of diseases |
| DK1708991T3 (da) * | 2004-01-22 | 2008-01-14 | Pfizer | Sulfonamid derivater til behandling af sygdomme |
| WO2005092861A1 (en) * | 2004-03-11 | 2005-10-06 | Pfizer Limited | Quinolinone derivatives pharmaceutical compositions containing them and their use |
| BRPI0508927A (pt) * | 2004-03-17 | 2007-08-14 | Pfizer | compostos úteis para o tratamento de doenças |
| WO2005092841A1 (en) * | 2004-03-23 | 2005-10-06 | Pfizer Limited | Compounds having beta-agonist activity |
| CA2560368A1 (en) * | 2004-03-23 | 2005-10-06 | Pfizer Inc. | Compounds for the treatment of diseases |
-
2004
- 2004-11-12 GB GB0425054A patent/GB0425054D0/en not_active Ceased
-
2005
- 2005-03-10 KR KR1020067019640A patent/KR100806478B1/ko not_active Expired - Fee Related
- 2005-03-10 MX MXPA06011019A patent/MXPA06011019A/es active IP Right Grant
- 2005-03-10 CA CA2560547A patent/CA2560547C/en not_active Expired - Fee Related
- 2005-03-10 ES ES05708714T patent/ES2343808T3/es not_active Expired - Lifetime
- 2005-03-10 SI SI200531057T patent/SI1730103T1/sl unknown
- 2005-03-10 RS RSP-2010/0339A patent/RS51438B/sr unknown
- 2005-03-10 PT PT05708714T patent/PT1730103E/pt unknown
- 2005-03-10 GE GEAP20059631A patent/GEP20084455B/en unknown
- 2005-03-10 DE DE602005021472T patent/DE602005021472D1/de not_active Expired - Lifetime
- 2005-03-10 JP JP2007504493A patent/JP4033892B2/ja not_active Expired - Fee Related
- 2005-03-10 EA EA200601544A patent/EA010133B1/ru not_active IP Right Cessation
- 2005-03-10 HR HR20100402T patent/HRP20100402T1/hr unknown
- 2005-03-10 DK DK05708714.0T patent/DK1730103T3/da active
- 2005-03-10 NZ NZ549839A patent/NZ549839A/en not_active IP Right Cessation
- 2005-03-10 AT AT05708714T patent/ATE469121T1/de active
- 2005-03-16 MY MYPI20051118A patent/MY144103A/en unknown
- 2005-03-18 HN HN2005000118A patent/HN2005000118A/es unknown
- 2005-03-18 SV SV2005002056A patent/SV2005002056A/es unknown
- 2005-03-21 PE PE2005000321A patent/PE20060264A1/es not_active Application Discontinuation
- 2005-03-22 NL NL1028597A patent/NL1028597C2/nl not_active IP Right Cessation
- 2005-03-22 TW TW094108791A patent/TWI335312B/zh not_active IP Right Cessation
- 2005-03-22 AR ARP050101118A patent/AR050236A1/es not_active Application Discontinuation
- 2005-03-23 DO DO2005000045A patent/DOP2005000045A/es unknown
- 2005-03-23 UY UY28819A patent/UY28819A1/es unknown
-
2006
- 2006-09-14 IL IL178102A patent/IL178102A/en not_active IP Right Cessation
- 2006-09-22 MA MA29335A patent/MA28480B1/fr unknown
- 2006-10-10 IS IS8552A patent/IS8552A/is unknown
- 2006-10-23 NO NO20064806A patent/NO20064806L/no not_active Application Discontinuation
-
2007
- 2007-09-14 JP JP2007239523A patent/JP4819770B2/ja not_active Expired - Fee Related
-
2010
- 2010-07-05 CY CY20101100620T patent/CY1112549T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007529499A5 (enExample) | ||
| JP2009530364A5 (enExample) | ||
| RU2009134512A (ru) | Гидрохлоридная соль 5-[3-(3-гидроксифенокси)азетедин-1-ил]-5-метил-2,2-дифенилгексанамида | |
| JP5567252B2 (ja) | グリコピロレートおよびベータ２アドレナリン受容体アゴニストの組合せ剤 | |
| EP2117542B1 (en) | Combinations of beta- 2 -adrenoceptor agonistic benzothiazolone | |
| ES2647486T3 (es) | Pirazolo[1,5-a]pirimidinas como agentes antivirales | |
| JP6392242B2 (ja) | 粘膜への水分付与が不十分であることが好都合である疾患の治療に有用なクロロ−ピラジンカルボキサミド誘導体 | |
| JP2021120408A (ja) | ３，５−ジアミノ−６−クロロ−ｎ−（ｎ−（４−（４−（２−（ヘキシル（２，３，４，５，６−ペンタヒドロキシヘキシル）アミノ）エトキシ）フェニル）ブチル）カルバミミドイル）ピラジン−２−カルボキサミド | |
| ES2293530T3 (es) | Derivados de sulfonamidas para el tratamiento de enfermedades. | |
| CN1289086C (zh) | 抗疟治疗药物的新用途 | |
| JP2009539828A5 (enExample) | ||
| JP2007522141A (ja) | 呼吸器疾患の処置のためのベンゾチアゾール−２−オンベータ２アドレナリン受容体アゴニストとコルチコステロイドの組合せ剤 | |
| RU2008129620A (ru) | Пиразиноилгуанидиновые соединения, применяемые в лечении воспалительных или аллергических заболеваний | |
| KR20130094784A (ko) | 포스포디에스테라제 억제제를 포함하는 건조 분말 제제 | |
| US20040147544A1 (en) | Pde4 inhibitor and an anti-cholinergic agent in combination for treating obstructive airways diseases | |
| RU2011110908A (ru) | Тиенопиримидины для фармацевтических композиций | |
| US20100144606A1 (en) | Combination 408 | |
| JP2011507878A5 (enExample) | ||
| RU2015121046A (ru) | Соединения, обладающие активностью антагонистов мускариновых рецепторов и агонистов бета-2-адренергических рецепторов | |
| CA2623332A1 (en) | Carboxamide derivatives as muscarinic receptor antagonists | |
| JP2008056680A5 (enExample) | ||
| KR20150095869A (ko) | 아릴알킬- 및 아릴옥시알킬-치환된 상피 나트륨 채널 차단 화합물 | |
| CA2705729A1 (en) | Pyrazole derivatives as 5-lo inhibitors | |
| US20150290192A1 (en) | Inhibitors of bruton's tyrosine kinase | |
| JP2009532413A5 (enExample) |